Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 68Breast Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Triple Negative Breast Neoplasms 28Squamous Cell Carcinoma of Head and Neck 15Neoplasms 11Head and Neck Neoplasms 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 7Stomach Neoplasms 6Melanoma 6Adenocarcinoma 6Esophageal Neoplasms 5Cholangiocarcinoma 5Advanced Pancreatic Cancer 5Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Small Cell Lung Carcinoma 3Recurrence 3Pathologic Complete Response 3Ovarian Neoplasms 3Neoplasms by Site 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Uveal Melanoma 2Uterine Cervical Neoplasms 2

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Biliary Tract Cancer × 130-nm albumin-bound paclitaxel × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡